Remove Communication Remove Drug Pricing Remove White Paper
article thumbnail

Inflation, drug pricing and reimbursement constraints will challenge pharma sector

Pharmaceutical Technology

The survey results also indicated that drug pricing and reimbursement constraints will be the second biggest concern, hampering the industry’s growth, as indicated by 30% of the surveyed respondents. To adapt is the only way to thrive. Please check your email to download the Report.

article thumbnail

The Brazilian pharma market: Key information and what may change

Pharmaceutical Technology

There are also strict price controls, which in some cases can limit profitability for manufacturers. Brazilian public spending on healthcare, drug pricing reforms and remote medicine. Despite this, Brazil’s trade protectionist policies mean that there are few pharmaceutical companies of international origin within the country.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Inflationary storm clouds will continue to buffet global pharma industry in 2023

Pharmaceutical Technology

The topic of inflation overlaps with drug pricing strategy themes. Policymakers are attempting to respond to inflation crises by introducing new frameworks on the regulation of drug prices. Similar echoes are heard in Europe, where pressure to curb price growth will stay a priority.

article thumbnail

Inflationary storm clouds will continue to buffet global pharma industry in 2023

Pharmaceutical Technology

The topic of inflation overlaps with drug pricing strategy themes. Policymakers are attempting to respond to inflation crises by introducing new frameworks on the regulation of drug prices. Similar echoes are heard in Europe, where pressure to curb price growth will stay a priority.

article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. These actions allegedly led to the extension of Novartis’ patents.

article thumbnail

How early planning leads to successful market access and drug launch in Europe

Pharmaceutical Technology

An example is NICE’s Quality Adjusted Life Year score, used to price drugs in the UK. Some nations such as France base their decisions on the drug’s medical benefit and clinical added value versus existing therapies. Please check your email to download the Case Study.

article thumbnail

NHC Comments on IRA Guidance Response

Putting Patients First Blog

10: External Data Submission Timing The NHC understands the tight timeline for the drug selection and price negotiation processes. As discussed in the NHC’s 2020 white paper on the topic,3 patient value is multi-faceted, and any attempts to distill important dimensions of patient value and benefit into a single number is fraught.